Alpha 2.0
Login Register
» Authors » Fuminaka Sugauchi

Fuminaka Sugauchi

Explore the profile of Fuminaka Sugauchi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 73
Citations 2368
Followers 0
Related Specialties
Gastroenterology
Microbiology
Infectious Diseases
Top 10 Co-Authors
Masashi Mizokami
Yasuhito Tanaka
Etsuro Orito
Ryuzo Ueda
Hideaki Kato
Tomoyoshi Ohno
Kentaro Matsuura
Seiji Suzuki
Namiki Izumi
Yuzo Miyakawa
Published In
J Med Virol
Hepatol Res
J Gastroenterol
J Gen Virol
J Virol
Affiliations
Soon will be listed here.
Recent Articles
1.
Application of a newly developed high-sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance
Shinkai N, Matsuura K, Sugauchi F, Watanabe T, Murakami S, Iio E, et al.
J Clin Microbiol . 2013 Aug; 51(11):3484-91. PMID: 23946517
We modified and automated a highly sensitive chemiluminescent enzyme immunoassay (CLEIA) for surface antigen (HBsAg) detection using a combination of monoclonal antibodies, each for a specific epitope of HBsAg, and...
2.
Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene
Watanabe T, Sugauchi F, Tanaka Y, Matsuura K, Yatsuhashi H, Murakami S, et al.
Gut . 2012 Nov; 62(9):1340-6. PMID: 23135762
Objective: Recent studies have demonstrated that genetic polymorphisms near the IL28B gene are associated with the clinical outcome of pegylated interferon α (peg-IFN-α) plus ribavirin therapy for patients with chronic...
3.
Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis
Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, et al.
Antivir Ther . 2012 Jan; 17(1):35-43. PMID: 22267467
Background: This study aimed to define factors associated with relapse among responders to pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy in chronic hepatitis C. Methods: A cohort of genotype 1b...
4.
[Quantitative analysis of hepatitis B surface antigen as a clinical marker]
Nakamura E, Kakuda H, Matsuura K, Sugauchi F, Shinkai N, Tanaka Y
Rinsho Byori . 2011 Nov; 59(9):838-43. PMID: 22111300
There are 1.5 million hepatitis B virus (HBV) infected patients in Japan. Anti-viral therapy is important for chronic hepatitis B patients to prevent hepatocellular carcinoma. Recently, HBs antigen (HBsAg) quantification...
5.
Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C
Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, et al.
J Hepatol . 2011 Oct; 56(3):602-8. PMID: 22027574
Background & Aims: Assessment of the risk of hepatocellular carcinoma (HCC) development is essential for formulating personalized surveillance or antiviral treatment plan for chronic hepatitis C. We aimed to build...
6.
Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin
Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, et al.
Antivir Ther . 2011 Aug; 16(5):685-94. PMID: 21817190
Background: A genome-wide association study revealed an association between variants of the inosine triphosphatase (ITPA) gene and ribavirin (RBV)-induced anaemia. The aim of this study was to replicate this finding...
7.
Pretreatment prediction of anemia progression by pegylated interferon alpha-2b plus ribavirin combination therapy in chronic hepatitis C infection: decision-tree analysis
Hiramatsu N, Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, et al.
J Gastroenterol . 2011 Jun; 46(9):1111-9. PMID: 21681410
Background: This study aimed to develop a model to predict the development of severe anemia during pegylated interferon alpha-2b plus ribavirin combination therapy. Methods: Data were collected from 1081 genotype...
8.
Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C
Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, et al.
Hum Mol Genet . 2011 Jun; 20(17):3507-16. PMID: 21659334
Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy. The aim of this study...
9.
Recommendation of lamivudine-to-entecavir switching treatment in chronic hepatitis B responders: Randomized controlled trial
Matsuura K, Tanaka Y, Kusakabe A, Hige S, Inoue J, Komatsu M, et al.
Hepatol Res . 2011 May; 41(6):505-11. PMID: 21585626
Aim:   In the 2007-2008 guidelines of the study group (Ministry of Health, Labor and Welfare of Japan), lamivudine (LAM)-continuous treatment was recommended in patients treated with LAM for more than...
10.
Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis
Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, et al.
J Med Virol . 2011 Jan; 83(3):445-52. PMID: 21264865
The aim of the present study was to clarify the significance of viral factors for pretreatment prediction of sustained virological response to pegylated-interferon (PEG-IFN) plus ribavirin (RBV) therapy for chronic...